Biotech Growth Trust (BIOG) has reported a disappointing set of annual results for the year ended 31 March 2025, with its net asset value (NAV) per share falling 24.4%, compared with a 6.0% decline for its benchmark, the NASDAQ Biotechnology Index (sterling-adjusted, total return). The trust’s share price fell 24.2%, closing the year on a … Continue reading Biotech Growth reports on tough year as sector faces macro and political headwinds